Core Insights - Biobeat Technologies has completed a $50 million Series B funding round, approximately 350 million RMB, led by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical, with participation from a strategic investor. The funds will primarily be used for the commercialization of its core product, the Biobeat non-cuff dynamic blood pressure monitoring system in the U.S. market [2] - The increasing number of hypertension patients highlights a shift in the clinical practice of dynamic blood pressure monitoring technology, with Biobeat being the first FDA-approved system for 24-hour continuous monitoring [2] Product Research Background - Hypertension is one of the most common chronic diseases, with over 100 million patients in the U.S. Despite the maturity of antihypertensive medications, adjustments in drug dosage heavily rely on physicians' assessments of patients' blood pressure [3] - Unlike diabetes management, which utilizes continuous glucose monitoring (CGM) for real-time insulin guidance, hypertension treatment lacks a similar continuous data foundation due to limitations in blood pressure monitoring methods [3] Current Monitoring Solutions - Traditional cuff-based ABPM is the most widely used device in clinical settings, consisting of a cuff, main unit, and data analysis software. While it is technically mature and included in clinical guidelines, it has limitations such as patient discomfort and low real-world usage rates [5] - Home electronic blood pressure monitors, including arm and wrist devices, are convenient but do not qualify as ABPM since they provide intermittent measurements triggered by patients, lacking continuous coverage of blood pressure variations [6] - Biobeat represents a new path with its patch-based, cuffless ABPM, allowing continuous monitoring without the discomfort of cuff inflation, aligning more closely with wearable device usage [7] Product Introduction - Biobeat's patch-based, cuffless blood pressure monitoring system enables 24-hour continuous monitoring by simply wearing a patch on the chest [8] - The system consists of a cuffless monitoring patch and accompanying mobile and computer applications, allowing patients to engage in daily activities and sleep without disruption. After monitoring, the patch can be disposed of by the patient, and reports are automatically generated and uploaded to electronic medical records [11] Company Overview - Biobeat Technologies is an innovative medical device company with operations in Tel Aviv, Israel, and Boca Raton, Florida, focusing on dynamic blood pressure monitoring. The company aims to enhance the application of ABPM among hypertension patients by capturing continuous blood pressure data while ensuring patient comfort and sleep quality [15] Conclusion - The integration of continuous blood pressure monitoring into standard clinical practices for hypertension management depends on clinical practice, physician acceptance, and payment environments. Biobeat has introduced a new technological option for dynamic blood pressure monitoring, and its practical application in clinical settings warrants ongoing attention [16]